High quality long read sequencing from low input DNA

基因组学是一个快速发展的领域，它不断受到测序技术发展的推动。为了保持在这个领域的领先地位，我们定期投资于最新的设备是很重要的。在此申请中，利物浦大学基因组研究中心（CGR）建议购买太平洋生物科学公司的Sequel II和femtoppulse系统，以扩展其目前的测序供应。这些仪器将提供新的、独特的能力——从有限的DNA中生成长读DNA序列数据，从而在从头基因组组装、微生物组分析、AMR和基因调控方面实现新的应用。CGR长期以来一直成功运行PacBio长读测序平台，并通过提供基因组技术来支持研究界。Sequel II将被放置在一个已建立的实验室中，该实验室拥有20名工作人员和价值约500万英镑的设备。我们在PacBio平台上的经验特别意味着Sequel II可以在到达后立即部署，取代我们的Sequel I平台，后者很快就会变得不经济，无法满足研究人员的期望，因此在功能上就会过时。

Genomics is a fast-moving field that is constantly been driven forward by developments in sequencing technology. To stay at the leading edge of this field it is important that we invest periodically in the latest equipment. In this application the Centre for Genomic Research (CGR) at the University of Liverpool proposes to purchase a Pacific Biosciences Sequel II and a FemtoPulse system to extend its current sequencing provision. These instruments will provide new, unique capability-- generation of long-read DNA sequence data from limited amounts of DNA, enabling new applications in de novo genome assembly, microbiome analysis, AMR and gene regulation. The CGR has a long-track record of successfully running PacBio long-read sequencing platforms and of supporting the research community by providing access to genomic technologies. The Sequel II will be placed in an established laboratory, with 20 staff and ~£5m of equipment. Our experience with PacBio platforms specifically means that the Sequel II can be deployed immediately on arrival, replacing our Sequel I platform, which will soon be uneconomical, unable to meet researchers' expectations, and hence functionally becoming obsolete.